ORAMED PHARMACEUTICALS INC. Other Significant Noncash Transaction, Value of Consideration Given
ORAMED PHARMACEUTICALS INC. (ORMP) reported Other Significant Noncash Transaction, Value of Consideration Given of $628.63 thousand for the 143-month period ending 2014-02-28, per its 10-Q filed 2014-04-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1 · last filed 2014-11-14
- ORAMED PHARMACEUTICALS INC. other significant noncash transaction, value of consideration given for the quarter ending 2013-08-31 was -$630.00.
- ORAMED PHARMACEUTICALS INC. other significant noncash transaction, value of consideration given for the quarter ending 2013-05-31 was $0.00.
- ORAMED PHARMACEUTICALS INC. other significant noncash transaction, value of consideration given for the quarter ending 2013-02-28 was $0.00.
- ORAMED PHARMACEUTICALS INC. other significant noncash transaction, value of consideration given for the quarter ending 2012-11-30 was $628.63K.
- ORAMED PHARMACEUTICALS INC. other significant noncash transaction, value of consideration given for fiscal 2013 was $628.00K.
| Period end | Other Significant Noncash Transaction, Value of Consideration Given 3 month | Other Significant Noncash Transaction, Value of Consideration Given 6 month | Other Significant Noncash Transaction, Value of Consideration Given 9 month | Other Significant Noncash Transaction, Value of Consideration Given 12 month | Other Significant Noncash Transaction, Value of Consideration Given 131 month | Other Significant Noncash Transaction, Value of Consideration Given 134 month | Other Significant Noncash Transaction, Value of Consideration Given 140 month | Other Significant Noncash Transaction, Value of Consideration Given 143 month |
|---|---|---|---|---|---|---|---|---|
| 2014-02-28 | $628.63K 10-Q · filed 2014-04-10 | |||||||
| 2013-11-30 | $628.63K 10-Q · filed 2014-01-14 | |||||||
| 2013-08-31 | -$630.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-11-14 | -$630.00 derived: sum of 2 quarters · filed 2014-11-14 | -$630.00 derived: sum of 3 quarters · filed 2014-11-14 | $628.00K 10-K · filed 2014-11-14 | ||||
| 2013-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-07-14 | $0.00 derived: sum of 2 quarters · filed 2014-07-14 | $628.63K 10-Q · filed 2014-07-14 | $628.63K 10-Q · filed 2013-07-17 | ||||
| 2013-02-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-04-10 | $628.63K 10-Q · filed 2014-04-10 | $628.63K 10-Q · filed 2013-04-11 | |||||
| 2012-11-30 | $628.63K 10-Q · filed 2014-01-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |